StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $2.97 | $3.00 | +1.01% | 0.1M |
| 05-11 | $3.01 | $3.03 | +0.66% | 0.1M |
| 05-12 | $3.00 | $2.95 | -1.67% | 0.1M |
| 05-13 | $2.95 | $2.90 | -1.69% | 0.1M |
| 05-14 | $2.95 | $2.89 | -2.03% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
No sell-side coverage available for ANIX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Annual 2023 2023-10-31 | Q3 2023 2023-07-31 | Q2 2023 2023-04-30 | Annual 2021 2021-10-31 |
|---|---|---|---|---|
Revenue | $210.00K | $210.00K | $210.00K | $512.00K |
Operating Income | $-11.01M | $-7.96M | $-5.12M | $-13.14M |
Net Income | $-9.81M | $-7.12M | $-4.61M | $-12.95M |
EPS (Diluted) | $-0.32 | $-0.23 | $-0.15 | $-0.45 |
Total Assets | $25.52M | $26.58M | $27.60M | $36.26M |
Total Liabilities | $2.15M | $1.99M | $1.69M | $1.49M |
Cash & Equivalents | $915.00K | $3.20M | $5.62M | $29.13M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 31.15M | 31.02M | 30.96M | 30.05M |
Fundamentals not available for ANIX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.